Metabolic dysfunction-associated fatty liver disease and insulin resistance in type 1 diabetes

Affiliations

¹ Clinical Diabetes/Healthy Ageing, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia. Electronic address: j.snaith@garvan.org.au.
² Department of Gastroenterology, St Vincent's Hospital Sydney, Darlinghurst, NSW, Australia.
³ Clinical Diabetes/Healthy Ageing, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia.

Comment

Jennifer R Snaith et al. Lancet Gastroenterol Hepatol. 2021 Dec.

. 2021 Dec;6(12):985-986.

doi: 10.1016/S2468-1253(21)00343-5.

¹ Clinical Diabetes/Healthy Ageing, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia. Electronic address: j.snaith@garvan.org.au.
² Department of Gastroenterology, St Vincent's Hospital Sydney, Darlinghurst, NSW, Australia.
³ Clinical Diabetes/Healthy Ageing, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia.

No abstract available

Conflict of interest statement

We declare no competing interests.

Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement.
Eslam M, Alkhouri N, Vajro P, Baumann U, Weiss R, Socha P, Marcus C, Lee WS, Kelly D, Porta G, El-Guindi MA, Alisi A, Mann JP, Mouane N, Baur LA, Dhawan A, George J. Eslam M, et al. Lancet Gastroenterol Hepatol. 2021 Oct;6(10):864-873. doi: 10.1016/S2468-1253(21)00183-7. Epub 2021 Aug 6. Lancet Gastroenterol Hepatol. 2021. PMID: 34364544 Review.